Dyslipidemia

A 62-year-old male with history of coronary artery disease and prior coronary bypass surgery eight years ago presents to the emergency department after having two days of intermittent shortness of breath since starting cephalexin (Keflex) for a skin infection three days ago. He states the shortness of breath seems to get worse about an hour after taking cephalexin (Keflex). Can you diagnose this patient?

A new study has found habitual tea drinkers lowered their risk of atherosclerotic cardiovascular disease, coronary heart disease, and stroke compared to never or non-habitual tea drinkers.

The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.

How women who undergo menopause before age 40 may be at a greater risk of heart disease.

The approval makes it the first indicated by the FDA for cardiovascular risk reduction among patients with elevated triglyceride levels, as an add-on to maximally tolerated statin therapy.

A review published in JAMA Cardiology reports that while patients with severe aortic stenosis are increasingly undergoing transcatheter aortic valve replacement (TAVR) procedures in place of surgery, there is little evidence on how best to utilize adjunctive antithrombotic therapy after the treatment.

How technology, innovation, and preventive care drove the last 10 years of improved public heart health.

Earlier this year, the American College of Cardiology and the American Heart Association updated treatment guidelines for the primary prevention of cardiovascular disease. They discourage the use of aspirin for this purpose, but in high-risk patients who are not at risk of bleeding, aspirin continues to be part of combination treatment regimens. In this slideshow, we highlight recent findings on aspirin use.

How findings from AHA show early ANGPTL3 and APOC3 benefits in cardiometabolic health, via liver protein targeting.

Discussing how new information released in 2019 has impacted the way cardiologists view aspirin use for primary and secondary prevention of cardiovascular events.

Novartis AG is set to acquire The Medicines Company in a $9.7 billion deal that is set to be completed in the first quarter of 2020.

Results of the CITU study are revealing more about the different impacts e-cigarette and tobacco use has on a patient's lipid profile.

A new analysis from the University of Minnesota has found many patients with and without an indication for regular low dose aspirin use are under or overusing the medication.

A new analysis from Johns Hopkins School of Medicine has found patients in the South, Midwest, and West were all more likely to report poorer healthcare-related quality of life when compared to patients in the Northeast.

The study author provides insight into the benefit of inclisiran in at-risk patients with ASCVD.

An analysis of 4 phase 3 clinical trials examining the use of bempedoic acid for lowering LDL cholesterol was presented at AHA 2019.